• HCV+ liver transplant: DAAs achieve 96% clearance rate in viremic recipients

    Study points to viability, decreased waitlist times.

  • Intra-arterial FOLFOX+sorafenib ups survival in HCC with portal vein invasion

    Nearly doubled OS vs frontline sorafenib alone.

  • American Radium Society issues evidence-based guidelines for anal cancer

    Appropriate use criteria for curative treatment of nonmetastatic disease.

  • Obstructive sleep apnoea linked to oesophageal cancer risk

    Severe obstructive sleep apnoea may indicate the need for endoscopic screening for Barrett's oesophagus.

  • New pancreatic NET sub-types help predict recurrence risk
    New pancreatic NET sub-types help predict recurrence risk

    Researchers found that non-functional pancreatic neuroendocrine tumours fall into two major sub-type categories.

  • Rectal cancer: successful neoadjuvant CRT may obviate need for adjuvant therapy

    Meta-analysis fails to present clear evidence supporting survival benefit.

  • Colorectal liver metastasis: bevacizumab vs cetuximab in head-to-head trial

    Phase 2 randomized trial of patients receiving front-line mFOLFOX6.

  • In HCC with portal vein tumor thrombus, this neoadjuvant therapy improves survival

    A previous, retrospective analysis had suggested that neoadjuvant 3D conformal radiotherapy may be effective in HCC with PVTT. This randomized trial provides direct evidence.

  • CRC screening: financial incentives fail to boost overall uptake

    Reward, lottery do increase FIT completion.

  • Metastatic CRC: adding 5-FU/LV boosts panitumumab maintenance

    Progression was significantly delayed after oxaliplatin-based induction therapy.

  • ESMO GI 2019: targeted therapy combination improves survival in colorectal cancer
    ESMO GI 2019: targeted therapy combination improves survival in colorectal cancer

    Data from the phase 3 BEACON CRC study presented at the ESMO World Congress on Gastrointestinal Cancer 2019.

  • ESMO GI 2019: colon cancer survival in patients with obesity and hyperglycaemia
    ESMO GI 2019: colon cancer survival in patients with obesity and hyperglycaemia

    New findings presented at the recent ESMO World Congress on Gastrointestinal Cancer 2019.

  • ESMO GI 2019: efficacy of flexible regorafenib dosing to relieve side effects
    ESMO GI 2019: efficacy of flexible regorafenib dosing to relieve side effects

    Results of the phase 2 REARRANGE study presented at the ESMO World Congress on Gastrointestinal Cancer 2019.

  • ESMO GI 2019: endoscopy vs. surgery for early oesophageal cancer
    ESMO GI 2019: endoscopy vs. surgery for early oesophageal cancer

    Study highlights “surprisingly low” risk of lymph node metastases and micrometastases with endoscopic treatment.

  • HPV vaccine could prevent thousands of cancers over the next few decades
    HPV vaccine could prevent thousands of cancers over the next few decades

    Estimates based on a modelling by the University of Warwick.

  • Hyperthyroidism: radioiodine tied to excess risk for cancer death

    Organ-absorbed doses positively associated with mortality from solid cancer.

  • CRC: low-dose leucovorin offers similar response, survival in meta-analysis

    The shortage in 2008 prompted a switch to lower doses.

  • Load more